Group 1 - Ryzneuta® (marketed as "亿立舒®" in China) has successfully completed its second shipment to the U.S. market, marking significant progress in its commercialization journey [1] - The drug was approved for sale in the U.S. in January 2023, and by May 2025, the first shipment to the U.S. market was completed, indicating a rapid acceleration in its commercialization process [1] - Acrotech, the U.S. partner, has increased its procurement volume and sales targets for Ryzneuta® based on optimistic clinical data and market potential, and plans to independently invest in research for an automatic injection version of the drug [1][2] Group 2 - Ryzneuta® is a novel long-acting G-CSF product and the only one in China that has undergone head-to-head clinical comparisons with both long-acting and short-acting reference products [2] - The drug has demonstrated superior clinical data, reducing the risk of neutropenia while significantly decreasing the frequency of administration for patients [2] - The U.S. market pricing for Ryzneuta® is set at $4,600 per unit, approximately 14 times the domestic price, reflecting the global market's recognition of the value of Chinese innovative drugs [2] Group 3 - Ryzneuta® was officially launched in the U.S. market in July 2023, and the second shipment occurred just two months later, driven by the partner's confidence in the drug's competitive advantages and market potential [3] - The drug is expected to gradually replace traditional G-CSF products, addressing market demands for long-acting and high-efficacy options [3] - In the first half of 2024, the sales revenue from the innovative drug business of the company increased by 169.57%, with Ryzneuta® alone achieving a shipment volume of over 220,000 units, a year-on-year increase of 96.02% [3]